Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs
Thomas Urban(Duke University), Paul B. Watkins(University of North Carolina at Chapel Hill), Itsik Pe’er(Columbia University), Ann K. Daly(Newcastle University), David B. Goldstein(Electronic BioSciences (United States)), Kevin V. Shianna(Duke University), Victor J. Navarro(Thomas Jefferson University Hospital), José Serrano(National Institutes of Health), Aris Floratos(Columbia University), Matthew R. Nelson(Deerfield (United States)), Yufeng Shen(Columbia University Irving Medical Center), Timothy J. Davern(California Pacific Medical Center), Dongliang Ge(Duke University), Robert J. Fontana(University of Michigan), Herbert L. Bonkovsky(Atrium Health Wake Forest Baptist), William M. Lee(The University of Texas Southwestern Medical Center), M. Isabel Lucena(Hospital Clínico Universitario Virgen de la Victoria), Naga Chalasani(Indiana University – Purdue University Indianapolis), Guruprasad P. Aithal(NIHR Nottingham Digestive Diseases Biomedical Research Unit), James Rochon(Clinical Research Institute), Andrew Stolz(University of Southern California), Jayant A. Talwalkar(Mayo Clinic), Mariam Molokhia(Auckland University of Technology)
Cited by 117
Related Papers
Finding the missing heritability of complex diseases
|Nature|2009|8.5k
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
|Nature Reviews Genetics|2008|3k